Introduction
Malignant transformation in experimental model systems requires cooperative mutations in multiple oncogenes and/or tumor suppressor genes (TSGs). 1 This paradigm of multistep oncogenesis has been best studied in human colorectal cancer, which appears to require at least seven independent genetic alterations for the fully malignant phenotype to be manifested. 2 Cytogenetic and molecular studies of leukemias have identified a wide variety of recurrent chromosomal translocations and other genetic alterations, many of which are linked to specific subtypes of disease. 3 It is clear that many of these abnormalities are pivotal for leukemogenesis, as the mutant proteins they produce induce neoplastic transformation in experimental models. The kinetics and time course of development of leukemia in animal models indicate that additional mutations are necessary for leukemogenesis. 4 Therefore, an important goal in understanding the molecular pathogenesis of leukemia is to define the potential interactions between different genetic abnormalities.
Non-random chromosomal translocations are a common hallmark of childhood acute lymphoblastic leukemias (ALLs). 5 A wide variety of 'primary' translocations have been identified. In B-lineage ALLs, these primary translocations typically Correspondence: SP Hunger, UCHSC Campus, Box C229; 4200 East Ninth Ave, Denver, CO 80262, USA; Fax: 303 315 3244 Received 14 November 1997; accepted 11 May 1998 create fusion proteins, many of which have structural features and functional properties of chimeric transcription factors. 3 It is uncommon for more than one 'primary' translocation to be observed in a single ALL. 6 When other cytogenetic abnormalities accompany a primary translocation, they are often numerical, thereby conferring an imbalance of gene copy number. 7 This suggests that the molecular abnormalities that cooperate with chimeric transcription factors are likely to include inactivation of TSGs via deletions and activation of oncogenes via point mutations or gene amplifications. 8 The p16
INK4A (p16) and p15 INK4B (p15) genes are located on the short arm of chromosome 9 (9p21) and encode proteins (p16 and p15) that function as inhibitors of the cyclin-dependent kinases CDK4 and CDK6. [8] [9] [10] In addition, p16 encodes a second protein, p19 ARF , which shares no amino acid homology with p16, via an alternative first exon (1␤) and translation of common exons 2 and 3 in a different reading frame.
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Knockout mice lacking either p19 ARF alone, or both p19 ARF and p16 have a high incidence of spontaneous tumor formation, indicating that p16 INK4A is a bona fide TSG. 12, 13 The p16 and p15 loci are altered by homozygous deletion, promoter hypermethylation or point mutation in a wide variety of human cancers. In childhood ALL, the primary mechanism of p16/p15 inactivation is via homozygous deletion, which occurs in more than 20% of cases, and is significantly more common in T-lineage than B-lineage ALLs. [14] [15] [16] p15 is also inactivated by promoter hypermethylation in a significant proportion of childhood T-ALLs. 17, 18 In contrast, p16 promoter hypermethylation and point mutations in either p16 or p15 are rarely identified in childhood ALLs.
While there is a significant amount of data on the incidence of p16 and p15 gene abnormalities in childhood ALL, very little information is available concerning the potential association between these abnormalities and specific chromosomal translocations. Ohnishi et al 16 found that homozygous p16 and/or p15 deletions were present in 13 of 60 (22%) primary childhood B-precursor ALL samples, a percentage that is consistent with findings of other investigators.
14 A striking finding of this study was the negative association between p16/p15 deletions and the t(1;19)(q23;p13): 0/13 primary t (1;19) + ALLs and 1/5 t(1;19) + ALL cell lines had p16 and/or p15 abnormalities as compared to 13/47 (28%) primary B-lineage ALLs and 9/10 (90%) cell lines lacking a t(1;19).
The t(1;19)(q23;p13) is one of the most common primary translocations in childhood ALL, occurring in approximately 5% of cases. 19 In approximately 95% of patients with a t(1;19), E2A is fused to PBX1, producing E2A-PBX1 chimeric proteins that play an important role in leukemogenesis. [20] [21] [22] In contrast, approximately 5% of t (1;19) + ALLs, despite containing translocations that appear identical at the cytogenetic level, lack molecular evidence of E2A or PBX1 abnormalities. 23 E2A is also the target of the t(17,19)(q22;p13), which occurs in 0.5-1% of childhood ALLs and results in production of E2A-HLF fusion proteins. 24, 25 E2A-PBX1 and E2A-HLF are both chimeric transcription factors which contain the same portions of E2A, including two experimentally defined transcriptional activation domains, fused to regions of PBX1 or HLF that contain unique DNA binding domains. E2A-PBX1 and E2A-HLF likely contribute to leukemogenesis via different mechanisms, as they bind to completely different DNA target sequences. 19 The reported negative association between the t(1;19) and p16 and p15 abnormalities prompted us to determine p16 and p15 gene status in additional t (1;19) + childhood ALLs, and compare this incidence to that observed in t (17;19) + ALLs.
Materials and methods

Specimens
HAL-01 and UOC-B1 t(17;19) + ALL cell lines (provided by Drs Kazuma Ohyashiki (Tokyo Medical College, Tokyo, Japan) and Stephen Smith (University of Chicago Medical Center, Chicago, IL, USA), respectively) have been described previously and shown to contain E2A-HLF cDNAs. 24, 25 Primary patient material used to establish the HAL-01 cell line was also kindly donated by Dr Ohyashiki. Two additional primary t (17;19) + ALL patient samples (DEN-R and RFH-N) that contain type II E2A-HLF fusion cDNAs have previously been described. 26 The t(1;19) + ALL cell line RCH-ACV contains E2A-PBX1 fusion mRNAs. 20 Twelve primary t(1;19) + ALL specimens were available for analysis. Six of these were originally obtained from the Pediatric Oncology Group ALL cell bank and have previously been demonstrated to contain E2A-PBX1 fusion mRNAs. 27 Six additional t(1;19) + ALL specimens were available from the cell bank of The Children's Hospital in Denver. All primary ALL specimens were originally collected as part of protocols that had been approved by the appropriate Institutional Review Boards (IRBs) and the current study was approved by the IRB of the University of Colorado Health Sciences Center.
Molecular analyses
Genomic DNA was isolated by standard phenol/chloroform extraction. High molecular weight DNA (5-10 g) was digested with appropriate restriction endonucleases, size-fractionated by electrophoresis in 0.8% agarose gel and transferred to charged nylon membranes (Zeto Probe; BioRad, Hercules, CA, USA). Membranes were hybridized as previously described 24 with probes that were radiolabeled with ␣ 32 PdCTP using the Random Primers DNA labeling system (Gibco BRL, Gaithersburg, MD, USA). To determine E2A gene status, blots containing BglII-digested DNAs were hybridized with an E2A cDNA probe. 20 To determine p16 and p15 gene status, membranes containing BamHI-digested DNAs were cohybridized with previously described p16 exon 2 and MLL cDNA probes. 28, 29 This p16 probe cross-hybridizes with p15, allowing assessment of both p16 and p15. Samples in which p16 and/or p15 bands were absent or were less than 10-20% of the intensities of control MLL bands were scored as containing homozygous deletions of the corresponding gene. Appropriate positive (DNA from a cell line known to contain homozygous deletions of p16 and p15) and negative (DNA from a healthy individual) controls were included on each blot.
To determine the methylation status of the p15 promoter region, membranes containing HindIII and EagI in combination with HindIII-digested DNAs were hybridized with a 270 bp p15 exon 1 probe that was generated by amplifying genomic DNA with previously described PCR primers 30 and cloning the product into the pCRII vector as recommended by the supplier (Invitrogen, San Diego, CA, USA). Appropriate positive (DNA from the Kg1A cell line, which is known to contain a hypermethylated p15 promoter) and negative (DNA from a healthy individual) controls were included on each blot.
Statistical analyses
Fisher's exact test comparisons were made using the SAS statistical package.
Results and discussion
We first determined E2A gene status in the six t(1; 19) + ALLs that had not previously been analyzed molecularly. Each of these six cases contained E2A gene rearrangements ( Figure 1 (Figure 2 ). In contrast, homozygous deletions of both p16 and p15 were detected in two of four independent t(17; 19) + samples analyzed, the cell lines HAL-01 and UOC-B1. Primary patient material used to establish the HAL-01 cell line also contained homozygous p16 and p15 deletions, indicating that the deletions occurred in the patient and not during establishment or propagation of the cell line (Figure 2) .
We next used the strategy outlined in Figure 3a to determine the methylation status of p15 exon 1 for the cases that lacked p15/p16 homozygous deletions. Sufficient DNA was available to perform this analysis on 10 of the 13 t(1;19) + samples, none of which showed evidence of p15 promoter hypermethylation. In contrast, one of the two t(17; 19) + ALLs that were p15/p16 germline (DEN-R in Figure 3b ) reproducibly showed both 2.8 kb and 0.6 kb bands on HindIII/EagI digests. The ratio of 2.8:0.6 kb bands was similar to that seen in a 1:1 mixture of methylated:unmethylated samples (data not shown), indicating either that p15 exon 1 was hemizygously hypermethylated, or there was a subpopulation, accounting for approximately half the cells, that was homozygously hypermethylated.
Our data, combined with that from Ohnishi et al, 16 demon- + RCH-ACV cell line; an E2A germline primary ALL sample; two primary t( + HAL-01 primary patient sample and cell line. Homozygous p16 and p15 deletions are present in K562, the E2A germline primary ALL sample, UOC-B1, HAL-01 patient and HAL-01 cell line. Faint residual p16 and p15 bands (Ͻ10%) in the E2A germline primary ALL and HAL-01 patient samples are due to contamination with small amounts of normal cells.
strate that homozygous p16 and/or p15 deletions are rare in t (1;19) + ALLs. Cumulatively in these two reports, homozygous deletions occurred in only one of 31 t(1; 19) + ALLs (0/25 patient samples and 1/6 cell lines). In contrast, we found that two of four t (17;19) + ALLs contained homozygous deletions of both p16 and p15 (P = 0.03) by the Fisher's exact test. Our data on p15 methylation status further indicate that p15 and p16 appear to be intact in the vast majority of t (1;19) + ALLs, and compromised in many t (17;19) + ALLs. These findings suggest that there likely are different modes of cooperative leukemogenesis in ALLs associated with different E2A chimeric transcription factors. These differences may reflect the fundamentally different biological properties of E2A-PBX1 and E2A-HLF. E2A-PBX1 promotes both proliferation and apoptosis in transgenic mice, and over-expression of Bcl-2 can suppress its pro-apoptotic activity in ALL cell lines. 31, 32 In contrast, E2A-HLF has potent anti-apoptotic properties, but does not promote proliferation. 33 Thus, alterations in apoptotic pathways may be needed to complement E2A-PBX1, while alterations in proteins that regulate proliferation and cell cycle progression may be necessary to complement E2A-HLF.
Since the deletions we observed in t(17;19) + ALLs involve p16 exon 2, they inactivate both p16 and p19 ARF proteins. It is remarkable that the three proteins encoded by p15 and p16 are involved in two major pathways that are most commonly targeted by mutations in human cancer: pRb/cyclin D/p16 and, to a lesser extent, p15, and p53/MDM2/p19 ARF . [34] [35] [36] Some information is known about the status of the other genes in these pathways in ALLs containing E2A translocations. In one study of childhood and adult ALLs, Rb was deleted in 2% of cases and pRb protein was absent in 33% of cases; none of these ALLs contained a visible t(1;19) or t (17;19) . 37 p53 mutations are present in about 2% of childhood ALLs at initial diagnosis. 38 Interestingly, one report found that p53 mutations occurred in 2/20 t(1; 19) + ALLs at diagnosis, 4/4 at relapse and 4/5 cell lines, 39 providing support for the hypothesis that mutations in apoptotic pathways are needed to complement E2A-PBX1. We are not aware of any data concerning the incidence of p53 mutations in t (17;19) + ALLs or over-expression of cyclin D or MDM2 in either t (1;19) + or t(17;19) + ALLs. Additional data suggest that other chimeric proteins produced by chromosomal translocations may be positively or negatively associated with homozygous p16 and/or p15 deletions. We reported previously that homozygous p16 or p15 deletions were not present in any of 54 infant ALLs analyzed, including 44 cases with MLL rearrangements. 29 Thus, at least in infant ALL, p16/p15 deletions do not appear to complement the activity of MLL protein chimeras. In contrast, p16/p15 deletions are detected in approximately 50% of CML cases in lymphoid blast crisis, but not in chronic phase or in myeloid blast crisis. 40 Similarly, although no molecular data on p16/p15 gene status were reported, 9p deletions were present in 17/66 (26%) adults with Philadelphia chromosomepositive ALL. 41 At this point in time, almost all of the translocations that are observed in Ͼ1% of ALLs and AMLs have been cloned, the involved genes have been identified, and their biochemical functions are under intensive study. 3 To date, p16 and p15 are the only TSGs identified that are inactivated in a significant percentage of leukemias. Cytogenetic studies have catalogued a number of regions of recurrent deletion in ALL and AML, indicating that additional TSGs important in leukemogenesis are likely to be identified in the near future. As these TSGs are identified, it will be essential to determine how different + patient samples; and the t(17;19) + DEN-R patient sample. Homozygous p15 hypermethylation is seen in Kg1A and hemizygous methylation in DEN-R. mutations co-segregate in order to understand the cooperative interplay between oncogene activation and TSG inactivation in leukemogenesis.
